Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options.
• Polo-like kinases (PLKs) are crucial regulators of cell division and survival, representing potential therapeutic targets in cancer.
• Targeting PLKs offers a promising strategy for novel ATC treatments.

Purpose of the Study:

• To evaluate the therapeutic efficacy of volasertib, a PLK inhibitor, as a single agent and in combination with sorafenib for ATC treatment.
• To investigate the effects of volasertib on ATC cell proliferation, cell cycle progression, and apoptosis.
• To assess the in vivo efficacy and safety of volasertib-based therapies in preclinical ATC models.

Main Methods:

• In vitro studies using ATC cell lines (8505C, 8305C, KAT18) treated with varying doses of volasertib.
• Cell cycle analysis (G2/M phase accumulation) and apoptosis assays (caspase-3 activity) were performed.
• In vivo studies involved xenograft models of ATC treated with volasertib alone or in combination with sorafenib.

Main Results:

• Volasertib demonstrated dose-dependent reduction in ATC cell viability.
• Volasertib induced G2/M cell cycle arrest and apoptosis in ATC cells.
• Combination therapy with volasertib and sorafenib exhibited synergistic effects in vitro and significant efficacy in 8505C xenografts.
• Single-agent volasertib effectively inhibited 8305C tumor growth with no significant observed toxicity.

Conclusions:

• Volasertib exhibits potent anti-cancer activity against anaplastic thyroid cancer cells.
• Combination therapy of volasertib and sorafenib is a promising strategy for ATC treatment.
• Volasertib represents a potential therapeutic agent for anaplastic thyroid cancer.